Networks of innovation: vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995
Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp a...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Cambridge
Cambridge University Press
1995
|
| Schlagworte: | |
| Online-Zugang: | BSB01 UBG01 URL des Erstveröffentlichers |
| Zusammenfassung: | Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp and Dohme, which acquired Mulford in 1929, and upon Merck & Co Inc., which merged with Sharp and Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw exclusively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals |
| Beschreibung: | Title from publisher's bibliographic system (viewed on 05 Oct 2015) |
| Beschreibung: | 1 online resource (xi, 273 pages) |
| ISBN: | 9780511629518 |
| DOI: | 10.1017/CBO9780511629518 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043927096 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 161202s1995 |||| o||u| ||||||eng d | ||
| 020 | |a 9780511629518 |c Online |9 978-0-511-62951-8 | ||
| 024 | 7 | |a 10.1017/CBO9780511629518 |2 doi | |
| 035 | |a (ZDB-20-CBO)CR9780511629518 | ||
| 035 | |a (OCoLC)967419447 | ||
| 035 | |a (DE-599)BVBBV043927096 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 |a DE-473 | ||
| 082 | 0 | |a 615/.372 |2 20 | |
| 084 | |a LC 56000 |0 (DE-625)90662:772 |2 rvk | ||
| 084 | |a XB 5200 |0 (DE-625)152477:12905 |2 rvk | ||
| 100 | 1 | |a Galambos, Louis |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Networks of innovation |b vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995 |c Louis Galambos with Jane Eliot Sewell |
| 264 | 1 | |a Cambridge |b Cambridge University Press |c 1995 | |
| 300 | |a 1 online resource (xi, 273 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Title from publisher's bibliographic system (viewed on 05 Oct 2015) | ||
| 520 | |a Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp and Dohme, which acquired Mulford in 1929, and upon Merck & Co Inc., which merged with Sharp and Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw exclusively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals | ||
| 610 | 2 | 4 | |a Merck, Sharp & Dohme International / History |
| 610 | 2 | 7 | |a Merck & Co. |0 (DE-588)5284383-X |2 gnd |9 rswk-swf |
| 648 | 7 | |a Geschichte 1895-1995 |2 gnd |9 rswk-swf | |
| 650 | 4 | |a Geschichte | |
| 650 | 4 | |a Vaccines / History | |
| 650 | 4 | |a Vaccines industry / History | |
| 650 | 0 | 7 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Impfstoff |0 (DE-588)4026655-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Merck & Co. |0 (DE-588)5284383-X |D b |
| 689 | 0 | 1 | |a Impfstoff |0 (DE-588)4026655-2 |D s |
| 689 | 0 | 2 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 0 | 3 | |a Geschichte 1895-1995 |A z |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a Sewell, Jane Eliot |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druckausgabe |z 978-0-521-56308-6 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druckausgabe |z 978-0-521-62620-0 |
| 856 | 4 | 0 | |u https://doi.org/10.1017/CBO9780511629518 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-20-CBO | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029336175 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1017/CBO9780511629518 |l BSB01 |p ZDB-20-CBO |q BSB_PDA_CBO |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1017/CBO9780511629518 |l UBG01 |p ZDB-20-CBO |q UBG_PDA_CBO |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804176855518937088 |
|---|---|
| any_adam_object | |
| author | Galambos, Louis |
| author_facet | Galambos, Louis |
| author_role | aut |
| author_sort | Galambos, Louis |
| author_variant | l g lg |
| building | Verbundindex |
| bvnumber | BV043927096 |
| classification_rvk | LC 56000 XB 5200 |
| collection | ZDB-20-CBO |
| ctrlnum | (ZDB-20-CBO)CR9780511629518 (OCoLC)967419447 (DE-599)BVBBV043927096 |
| dewey-full | 615/.372 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.372 |
| dewey-search | 615/.372 |
| dewey-sort | 3615 3372 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin Sozial-/Kulturanthropologie / Empirische Kulturwissenschaft |
| doi_str_mv | 10.1017/CBO9780511629518 |
| era | Geschichte 1895-1995 gnd |
| era_facet | Geschichte 1895-1995 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03377nmm a2200589zc 4500</leader><controlfield tag="001">BV043927096</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">161202s1995 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780511629518</subfield><subfield code="c">Online</subfield><subfield code="9">978-0-511-62951-8</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1017/CBO9780511629518</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-20-CBO)CR9780511629518</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)967419447</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043927096</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield><subfield code="a">DE-473</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.372</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">LC 56000</subfield><subfield code="0">(DE-625)90662:772</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XB 5200</subfield><subfield code="0">(DE-625)152477:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Galambos, Louis</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Networks of innovation</subfield><subfield code="b">vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995</subfield><subfield code="c">Louis Galambos with Jane Eliot Sewell</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge</subfield><subfield code="b">Cambridge University Press</subfield><subfield code="c">1995</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xi, 273 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Title from publisher's bibliographic system (viewed on 05 Oct 2015)</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp and Dohme, which acquired Mulford in 1929, and upon Merck & Co Inc., which merged with Sharp and Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw exclusively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">Merck, Sharp & Dohme International / History</subfield></datafield><datafield tag="610" ind1="2" ind2="7"><subfield code="a">Merck & Co.</subfield><subfield code="0">(DE-588)5284383-X</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="648" ind1=" " ind2="7"><subfield code="a">Geschichte 1895-1995</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Geschichte</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vaccines / History</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vaccines industry / History</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Impfstoff</subfield><subfield code="0">(DE-588)4026655-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Merck & Co.</subfield><subfield code="0">(DE-588)5284383-X</subfield><subfield code="D">b</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Impfstoff</subfield><subfield code="0">(DE-588)4026655-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Geschichte 1895-1995</subfield><subfield code="A">z</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sewell, Jane Eliot</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druckausgabe</subfield><subfield code="z">978-0-521-56308-6</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druckausgabe</subfield><subfield code="z">978-0-521-62620-0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1017/CBO9780511629518</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-20-CBO</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029336175</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1017/CBO9780511629518</subfield><subfield code="l">BSB01</subfield><subfield code="p">ZDB-20-CBO</subfield><subfield code="q">BSB_PDA_CBO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1017/CBO9780511629518</subfield><subfield code="l">UBG01</subfield><subfield code="p">ZDB-20-CBO</subfield><subfield code="q">UBG_PDA_CBO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043927096 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:38:49Z |
| institution | BVB |
| isbn | 9780511629518 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029336175 |
| oclc_num | 967419447 |
| open_access_boolean | |
| owner | DE-12 DE-473 DE-BY-UBG |
| owner_facet | DE-12 DE-473 DE-BY-UBG |
| physical | 1 online resource (xi, 273 pages) |
| psigel | ZDB-20-CBO ZDB-20-CBO BSB_PDA_CBO ZDB-20-CBO UBG_PDA_CBO |
| publishDate | 1995 |
| publishDateSearch | 1995 |
| publishDateSort | 1995 |
| publisher | Cambridge University Press |
| record_format | marc |
| spelling | Galambos, Louis Verfasser aut Networks of innovation vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995 Louis Galambos with Jane Eliot Sewell Cambridge Cambridge University Press 1995 1 online resource (xi, 273 pages) txt rdacontent c rdamedia cr rdacarrier Title from publisher's bibliographic system (viewed on 05 Oct 2015) Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp and Dohme, which acquired Mulford in 1929, and upon Merck & Co Inc., which merged with Sharp and Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw exclusively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals Merck, Sharp & Dohme International / History Merck & Co. (DE-588)5284383-X gnd rswk-swf Geschichte 1895-1995 gnd rswk-swf Geschichte Vaccines / History Vaccines industry / History Arzneimittelentwicklung (DE-588)4143176-5 gnd rswk-swf Impfstoff (DE-588)4026655-2 gnd rswk-swf Merck & Co. (DE-588)5284383-X b Impfstoff (DE-588)4026655-2 s Arzneimittelentwicklung (DE-588)4143176-5 s Geschichte 1895-1995 z 1\p DE-604 Sewell, Jane Eliot Sonstige oth Erscheint auch als Druckausgabe 978-0-521-56308-6 Erscheint auch als Druckausgabe 978-0-521-62620-0 https://doi.org/10.1017/CBO9780511629518 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Galambos, Louis Networks of innovation vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995 Merck, Sharp & Dohme International / History Merck & Co. (DE-588)5284383-X gnd Geschichte Vaccines / History Vaccines industry / History Arzneimittelentwicklung (DE-588)4143176-5 gnd Impfstoff (DE-588)4026655-2 gnd |
| subject_GND | (DE-588)5284383-X (DE-588)4143176-5 (DE-588)4026655-2 |
| title | Networks of innovation vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995 |
| title_auth | Networks of innovation vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995 |
| title_exact_search | Networks of innovation vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995 |
| title_full | Networks of innovation vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995 Louis Galambos with Jane Eliot Sewell |
| title_fullStr | Networks of innovation vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995 Louis Galambos with Jane Eliot Sewell |
| title_full_unstemmed | Networks of innovation vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995 Louis Galambos with Jane Eliot Sewell |
| title_short | Networks of innovation |
| title_sort | networks of innovation vaccine development at merck sharp dohme and mulford 1895 1995 |
| title_sub | vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995 |
| topic | Merck, Sharp & Dohme International / History Merck & Co. (DE-588)5284383-X gnd Geschichte Vaccines / History Vaccines industry / History Arzneimittelentwicklung (DE-588)4143176-5 gnd Impfstoff (DE-588)4026655-2 gnd |
| topic_facet | Merck, Sharp & Dohme International / History Merck & Co. Geschichte Vaccines / History Vaccines industry / History Arzneimittelentwicklung Impfstoff |
| url | https://doi.org/10.1017/CBO9780511629518 |
| work_keys_str_mv | AT galamboslouis networksofinnovationvaccinedevelopmentatmercksharpdohmeandmulford18951995 AT sewelljaneeliot networksofinnovationvaccinedevelopmentatmercksharpdohmeandmulford18951995 |